Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|December 17, 2020
Dr. Ramaprasad Srinivasan highlights the latest treatment advances in kidney cancer
Author(s)Urology Times staff
The comprehensive review includes key developments in both clear cell and non-clear cell histology.
Advertisement
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, summarizes the latest advances in the treatment paradigm for patients with renal cell carcinoma (RCC).
At the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared data on one of these advances: a
In this video, Srinivasan provides a comprehensive review the latest breakthroughs in all areas of RCC, including both clear cell and non-clear cell histology.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement